In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $420.41, a high estimate of $570.00, and a low estimate of $333.00.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...

Disc Medicine has charted a route to market for its bitopertin drug for rare disease erythropoietic protoporphyria.

The Windsors have always exuded an air of mystique, so it's not surprising there are so many wild royal family conspiracy ...

Market Wrap Clinuvel (CUV) Shares in biopharmaceutical company Clinuvel have recently benefited from positive preliminary results in its phase three porphyria trial. Updated Dec 22, 2009 Joyce ...

Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Pharma – it has just agreed to acquire the biotech for $3.3 billion ...

The LED face mask is the newest accessory in a celebritys skincare routine kit However do these sci-fi-looking devices work ...

CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 ...